Vitamin D: Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
No edit summary
No edit summary
Line 16: Line 16:
* [Vitamin D supplementation and total cancer incidence and mortality - British Journal of Cancer](https://www.nature.com/articles/s41416-020-01188-1)
* [Vitamin D supplementation and total cancer incidence and mortality - British Journal of Cancer](https://www.nature.com/articles/s41416-020-01188-1)
|toxicity_level=2
|toxicity_level=2
|toxicity_explanation=
|toxicity_explanation=
|toxicity_explanation=
|toxicity_explanation=
|toxicity_explanation=
}}
}}

Revision as of 08:32, 27 March 2024

Property Information
Drug Name Vitamin D (Alfacalcidol, Paricalcitol, Cholecalciferol variants)
FDA Approval No
Used for Glioblastoma Multiforme (GBM), various types of cancer
Clinical Trial Phase Various studies, including recent meta-analyses and reviews
Clinical Trial Explanation Not specified
Common Side Effects Hypercalcemia at high doses of calcitriol; other forms generally safe
OS without Not explicitly detailed in recent reviews
OS with Recent meta-analyses suggest potential for improving cancer treatment outcomes
PFS without Not specified
PFS with Not specified
Usefulness Rating 4
Usefulness Explanation Not specified
Toxicity Level 2
Toxicity Explanation

Notes: Recent reviews underscore Vitamin D's potential in cancer prevention and treatment, emphasizing its impact on biological mechanisms related to cancer regulation and its possible synergistic effects with chemo/immunotherapeutic drugs. The dosage and supplementation strategies are critical for optimizing its therapeutic benefits.

Links: * [The impact of vitamin D on cancer: A mini review - PubMed](https://pubmed.ncbi.nlm.nih.gov/37054849/)

From Ben Williams Book: Not specified

Loading comments...